The WACC of Hua Medicine (2552.HK) is 9.3%.
| Range | Selected | |
| Cost of equity | 7.90% - 11.70% | 9.80% |
| Tax rate | 22.10% - 22.30% | 22.20% |
| Cost of debt | 5.00% - 5.00% | 5.00% |
| WACC | 7.5% - 11.0% | 9.3% |
| Category | Low | High |
| Long-term bond rate | 2.9% | 3.4% |
| Equity market risk premium | 6.0% | 7.0% |
| Adjusted beta | 0.84 | 1.13 |
| Additional risk adjustments | 0.0% | 0.5% |
| Cost of equity | 7.90% | 11.70% |
| Tax rate | 22.10% | 22.30% |
| Debt/Equity ratio | 0.1 | 0.1 |
| Cost of debt | 5.00% | 5.00% |
| After-tax WACC | 7.5% | 11.0% |
| Selected WACC | 9.3% | |
The Cost of Equity reflects the return a company needs to deliver to shareholders to justify the risk of investing in its shares. It’s computed using the Capital Asset Pricing Model (CAPM), which blends the risk-free rate, the stock’s beta, and the market risk premium.
This method evaluates the stock’s risk compared to a safe investment and the market’s overall volatility.
Here’s how we figure out the cost of equity for 2552.HK:
cost_of_equity (9.80%) = risk_free_rate (3.15%) + equity_risk_premium (6.50%) * adjusted_beta (0.84) + risk_adjustments (0.25%)
We include the risk adjustments, which range from 0% to 1%, to keep our WACC conservatives, especially for companies traded in developing markets.